Sanara MedTech Inc (SMTI) — Titan Protect Analysis

SMTI

Sanara MedTech Inc

Healthcare · ·

$22.44

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$194M

Total market value of the company

Trailing P/E

353.50

Expensive — high growth expected

Forward P/E

39.28

Based on estimated future earnings — lower means cheaper

Rev Growth

+18.6%

Year-over-year revenue change

Profit Margin

-31.2%

How much profit the company keeps from each dollar of revenue

ROE

2.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$34.00

+52% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Sanara MedTech Inc

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; F

https://sanaramedtech.com

Country: United States Employees: 108 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.090

Positive but modest risk-adjusted returns

Kelly Fraction

0.0005

Marginal edge — very small allocation suggested

Calmar Ratio

-0.192

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.9%

Historical annualised return based on price data

Max Drawdown

-57.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.16

Moves slightly more than the broader market

52W High

$35.95

38% below the year high

52W Low

$16.05

40% above the year low

Avg Volume

57,066

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.06

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

689.01

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

92.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

9.5%

Profit from core operations before interest and tax

Free Cash Flow

$6M

Positive — the business generates more cash than it spends

Revenue (TTM)

$107M

Total revenue over the last 12 months

Net Income

$630,718

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$36.00

Target Median

$34.00

Target Low

$32.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go